Patient Pulse

Weight Loss and CV Outcomes with Ozempic, Munjaro and Similar Drugs with Dr. Peter Toth

Thomas Nero, MD Season 2 Episode 3

Let us know your thoughts. We would love to hear from you.

Dr Peter Toth discusses with Dr. Thomas Nero the new classes of diabetes medications, SGLT2 inhibitors (eg Jardiance) and GLP1 receptor agonists (eg Ozempic and Munjaro.)  These drugs have been in the news due to an impressive effect on weight reduction, but they also improve cardiovascular outcomes in diabetic and non-diabetic patients.